cancer vaccine
Ultimovac CEO: "Data can place us at the forefront of cancer vaccines"
Ultimovacs has announced positive survival data from the phase II NIPU study evaluating the universal cancer vaccine UV1 in malignant mesothelioma. For...
Ultimovac's CMO explains Phase II data for mesothelioma
Ultimovacs has announced topline data from the Phase II NIPU study...
AACR focuses on personalized cancer vaccines
Moderna received a lot of attention when clinical...
Ultimovacs updates timeline for INITIUM study
The phase II trial INITIUM with Ultimovac's universal cancer vaccine UV1...
Mendus presents NK cell data at Innate Killer Summit
Mendus presented additional data for the company's proprietary DCOne platform...
Ultimovacs on the way to Phase II readout
Cancer vaccines are rapidly gaining popularity in the international biotechnology sector,...
Evaxion receives Fast Track for cancer vaccine candidate
2023 is off to a good start for Evaxion Biotech. After...
Mendus presents proof-of-concept data for maintenance treatment of AML
Acute myeloid leukemia often relapses, leading to...
The innovative force behind Ultimovac's cancer vaccine
Promising clinical data reinforces the fact that Ultimovac's universal...
Evaxion presents new strategic focus
Now that Per Norlén has taken over as...
Ultimovacs ready for the next step in clinical development
In its latest quarterly report, Norwegian immuno-oncology company Ultimovacs highlights...
Ultimovacs presents positive three-year data in skin cancer
The Norwegian biotechnology company Ultimovacs has recently presented positive...